Profit surges at Pfizer in 2Q on lower taxes, drug sales
Pfizer's second-quarter profit surged 26 percent, thanks to a 4 percent increase in medicine sales, higher income from partnerships and lower tax expenses.
Jul 31, 2018
0
0
Pfizer's second-quarter profit surged 26 percent, thanks to a 4 percent increase in medicine sales, higher income from partnerships and lower tax expenses.
Jul 31, 2018
0
0
Eli Lilly is planning an initial public offering for part of an animal health business that brought in about 13 percent of all company revenue last year.
Jul 24, 2018
0
3
Valeant Pharmaceuticals, which fell under withering scrutiny after acquiring the rights to drugs and then drastically raising their prices, is changing its name.
May 8, 2018
0
3
Pfizer posted slightly higher sales and a 14 percent jump in profit in the first quarter, thanks to lower restructuring costs and a much-lower tax rate, but its revenue still missed Wall Street expectations.
May 1, 2018
0
2
Merck posted an 18 percent jump in first-quarter income, beating Wall Street expectations, as reduced spending on marketing, administration and research easily offset lower medicine sales outside the U.S.
May 5, 2016
0
1
New York is a city of extreme inequality, where people in the poorest neighborhood of Brooklyn die 11 years earlier than those living around Wall Street, according to data released Wednesday.
Oct 14, 2015
0
14
Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.
Jan 27, 2015
0
2
Pfizer Inc.'s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line.
Jan 27, 2015
0
2
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.
Oct 27, 2014
0
0
Merck & Co. reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.
Feb 5, 2014
0
0